Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: Design, synthesis and biological evaluation

Molecular Diversity

Volumn 18, Issue 2, 2014, Pages 357-373

  Lesma, Giordano ^a   Sacchetti, Alessandro ^b   Bai, Rouli ^c   Basso, Giuseppe ^d   Bortolozzi, Roberta ^d   Hamel, Ernest ^c   Silvani, Alessandra ^a   Vaiana, Nadia ^a   Viola, Giampietro ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antimitotic peptides; Cytotoxicity; Dynamic resolution; Hemiasterlin; Tubulin

Indexed keywords

2 [(IT TERT BUTOXYCARBONYL)(METHYL)AMINO] 3 METHYL 3 PHENYLBUTANOIC ACID; 3 [2 METHYL 1 (METHYLAMINO)PROPYL] 1,2,4 OXADIAZOL 5(4H) ONE HYDROCHLORIDE; 3 [N,3 DIMETHYL 2 [3 METHYL 2 (METHYLAMINO) 3 PHENYLBUTANAMIDO]BUTANAMIDO] 4 METHOXYBENZOIC ACID TRIFLUOROACETATE; 3 [N,3 DIMETHYL 2 [3 METHYL 2 (METHYLAMINO) 3 PHENYLBUTANAMIDO]BUTANAMIDO]4 METHYLBENZOIC ACID TRIFLUOROACETATE; 3 [N,3 DIMETHYL 2 [3 METHYL 2 (METHYLAMINO) 3 PHENYLBUTANAMIDO]BUTANAMIDO]BENZOIC ACID TRIFLUOROACETATE; ANTIMITOTIC AGENT; ETHYL 2 [1 [(TERT BUTOXYCARBONYL)(METHYL)AMINO] 2 METHYLPROPYL]OXAZOLE 4 CARBOXYLATE; ETHYL 2 [2 METHYL 1 (METHYLAMINO)PROPYL]OXAZOLE 4 CARBOXYLATE HYDROCHLORIDE; ETHYL 3 (METHYLAMINO)BENZOATE; ETHYL 3 [2 [(2,3) 4 TERT BUTOXY 3 METHYL 4 OXO 2 (2 PHENYLPROPAN 2 YL)BUTANAMIDO] N,3 DIMETHYLBUTANAMIDO] 4 METHOXYBENZOATE; ETHYL 3 [2 [(TERT BUTOXYCARBONYL)AMINO] N,3 DIMETHYLBUTANAMIDO]BENZOATE; ETHYL 3 [2 [2 [(TERT BUTOXYCARBONYL)METHYLAMINO] 3 METHYL 3 PHENYLBUTANAMIDO]N,3 DIMETHYLBUTANAMIDO]BENZOATE; HEMIASTERLIN ANALOGUE; METHYL 2 AMINO 3 METHYL 3 PHENYLBUTANOATE; METHYL 2 [(TERT BUTOXYCARBONYL)AMINO] 3 METHYL 3 PHENYLBUTANOATE; METHYL 3 METHYL 2 OXO 3 PHENYLBUTANOATE; METHYL 3 [2 [(TERT BUTOXYCARBONYL)AMINO] N,3 DIMETHYLBUTANAMIDO] 4 METHOXYBENZOATE; METHYL 3 [2 [(TERT BUTOXYCARBONYL)AMINO] N,3 DIMETHYLBUTANAMIDO] 4 METHYLBENZOATE; METHYL 3 [2 [2 [(TERT BUTOXYCARBONYL)METHYLAMINO] 3 METHYL 3 PHENYLBUTANAMIDO] N,3 DIMETHYLBUTANAMIDO]BENZOATE; METHYL 4 METHOXY 3 (METHYLAMINO)BENZOATE; METHYL 4 METHYL 3 (METHYLAMINO)BENZOATE; N,2 DIMETHYL 1 (1H TETRAZOL 5 YL)PROPAN 1 AMINE HYDROCHLORIDE; TERT BUTYL (1 AMINO 3 METHYL 1 OXOBUTAN 2YL)(METHYL)CARBAMATE; TERT BUTYL (1 CYANO 2 METHYLPROPYL)(METHYL)CARBAMATE; TERT BUTYL METHYL [2 METHYL 1 (5 OXO 4,5 DIHYDRO 1,2,4 OXADIAZOL 3 YL)PROPYL)CARBAMATE; TERT BUTYL METHYL[2 METHYL 1 (1H TETRAZOL 5YL)PROPYL]CARBAMATE; TERT BUTYL [1 AMINO 1 (HYDROXYIMINO) 3 METHYLBUTAN 2 YL](METHYL)CARBAMATE; TRIPEPTIDE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; HEMIASTERLIN; HETEROCYCLIC COMPOUND; OLIGOPEPTIDE; TUBULIN MODULATOR;

ARTICLE; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; HYDROGEN BOND; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; HETEROCYCLIC COMPOUNDS; HUMANS; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; TUBULIN; TUBULIN MODULATORS;

EID: 84898801609     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-014-9507-9     Document Type: Article

References (38)

1. Kingston DGI (2009) Tubulin-interactive natural products as anticancer agents. J Nat Prod 72:507-515. doi: 10.1021/np800568j
2. Beckers T, Mahboobi S (2003) Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy. Drugs Fut 28:767. doi: 10.1358/dof.2003.028.08.744356
3. Jordan A, Hadfield JA, Lawrence NJ, McGown AT (1998) Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 18:259-296. doi: 10.1002/(SICI)1098-1128(199807)18:4<259:AID-MED3>3.0. CO;2-U
4. Ganguly A, Cabral F (2011) New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta 1816:164-171. doi: 10.1016/j.bbcan.2011.06.001
5. Mania S, Macapinlac M, Goel S, Verdier-Pinard D, Fojo T, Rothenberg M, Colevas D (2004) The clinical development of new mitotic inhibitors that stabilize the microtubule. Anti-Cancer Drugs 15:553-558. doi: 10.1097/01.cad.0000131681.21637.b2
6. Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790-803. doi: 10.1038/nrd3253
7. Molinski TF, Dalisay DS, Lievens SL, Saludes JP (2009) Drug development from marine natural products. Nat Rev Drug Discov 8:69-85. doi: 10.1038/nrd2487
8. Coleman JE, de Silva ED, Fangming K, Andersen RJ, Allen TM (1995) Cytotoxic peptides from the marine sponge Cymbastela sp. Tetrahedron 51:10653-10662. doi: 10.1016/0040-4020(95)00646-P
9. Gamble WR, Durso NA, Fuller RW, Westergaard CK, Johnson TR, Sackett DL, Hamel E, Cardellina JH 2nd, Boyd MR (1999) Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges. Bioorg Med Chem 7:1611-1615. doi: 10.1016/S0968-0896(99)00089-9
10. Talpir R, Benayahu Y, Kashman Y, Pannell L, Schleyer M (1994) Hemiasterlin and geodiamolide TA; two new cytotoxic peptides from the marine sponge Hemiasterella minor (Kirkpatrick). Tetrahedron Lett 35:4453-4456. doi: 10.1016/S0040-4039(00)73382-X
11. Anderson HJ, Coleman JE, Andersen RJ, Roberge M (1997) Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 39:223-226. doi: 10.1007/s002800050564.ISSN:0344-5704
12. Bai R, Durso NA, Sackett DL, Hamel E (1999) Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38:14302-14310. doi: 10.1021/bi991323e
13. Vedejs E, Kongkittingam C (2001) A total synthesis of (-)-hemiasterlin using N-Bts methodology. J Org Chem 66:7355-7364. doi: 10.1021/jo0104882
14. Kuznetsov G, TenDyke K, Towle MJ, Cheng H, Liu J, Marsh JP, Schiller SER, Spyvee MR, Yang H, Seletsky BM, Shaffer CJ, Marceau V, Yao Y, Suh EM, Campagna S, Fang FG, Kowalczyk JJ, Littlefield BA (2009) Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol Cancer Ther 8:2852-2860. doi: 10.1158/1535-7163.MCT-09-0301
15. Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Suayan R, Yamashita A, Cole D, Tang Z, Krishnamurthy G, Williamson R, Khafizova G, Musto S, Hernandez R, Annable T, Yang X, Discafani C, Beyer C, Greenberger LM, Loganzo F, Ayral-Kaloustian S (2004) Synthesis and biological activity of analogues of the antimicrotubule agent N, β, β -Trimethyl-l-phenylalanyl-N1-[(1S, 2E)-3-carboxy-1-isopropylbut-2-enyl]- N1,3-dimethyl-l-valinamide (HTI-286). J Med Chem 47:4774-4786. doi: 10.1021/jm040056u
16. Niu C, Ho DM, Zask A, Ayral-Kaloustian S (2010) Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies. Bioorg Med Chem Lett 20:1535-1538. doi: 10.1016/j.bmcl.2010.01.047
17. Zask A, Kaplan J, Musto S, Loganzo F (2005) Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents. J Am Chem Soc 127:17667-17671. doi: 10.1021/ja053663v
18. Hadaschik BA, Adomat H, Fazli L, Fradet Y, Andersen RJ, Gleave ME, So A (2008) Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. Clin Cancer Res 14:1510-1518. doi: 10.1158/1078-0432.CCR-07-4475
19. Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME (2008) Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. Int J Cancer 122:2368-2376. doi: 10.1002/ijc.23406
20. Ayral-Kaloustian S, Zask A (2005) Taltobulin. Drugs Fut 30:254. doi: 10.1358/dof.2005.030.03.886482
21. Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AAJr, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM (2004) Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α -tubulin. Mol Cancer Ther 3:1319-1327
22. Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM (2003) HTI-286, A synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 63:1838-1845
23. Nieman JA, Coleman JE, Wallace DJ, Piers E, Lim LY, Roberge M, Andersen RJ (2003) Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. J Nat Prod 66:183-199. doi: 10.1021/np020375t
24. Andersen RJ, Coleman JE, Piers E, Wallace DJ (1997) Total synthesis of (-)-hemiasterlin, a structurally novel tripeptide that exhibits potent cytotoxic activity. Tetrahedron Lett 38:317-320. doi: 10.1016/S0040-4039(96)02335-0
25. Hsu L-C, Durrant DE, Huang C-C, Chi N-W, Baruchello R, Rondanin R, Rullo C, Marchetti P, Grisolia G, Simoni D, Lee RM (2012) Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor. Invest New Drugs 30:1379-1388. doi: 10.1007/s10637-011-9702-9
26. Simoni D, Lee RM, Durrant DE, Chi N-W, Baruchello R, Rondanin R, Rullo C, Marchetti P (2010) Versatile synthesis of new cytotoxic agents structurally related to hemiasterlins. Bioorg Med Chem Lett 20:3431-3435. doi: 10.1016/j.bmcl.2010.03.098
27. Qie J, Zhou W, Zhao X, He J, Zhang Y, Liu K (2009) Hemiasterlin analogues with unnatural amino acids at the N-terminal and their inhibitory activity on tumor cells. Int J Pept Res Ther 15:187-194. doi: 10.1007/s10989-009-9168-1
28. Yamashita A, Norton EB, Kaplan JA, Niu C, Loganzo F, Hernandez R, Beyer CF, Annable T, Musto S, Discafani C, Zask A, Ayral-Kaloustian S (2004) Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment. Bioorg Med Chem Lett 14:5317-5322. doi: 10.1016/j.bmcl.2004.08.024
29. Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Yamashita A, Beyer C, Krishnamurthy G, Greenberger LM, Loganzo F, Ayral-Kaloustian S (2004) D-Piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors. Bioorg Med Chem Lett 14:4353-4358. doi: 10.1016/j.bmcl.2004.05.005
30. Milton MJ, Thomas Williamson R (2006) Mapping the bound conformation and protein interactions of microtubule destabilizing peptides by STD-NMR spectroscopy. Bioorg Med Chem Lett 16:4279-4282. doi: 10.1016/j.bmcl.2006.05.067
31. Ravi M, Zask A, Rush TS (2005) Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin. Biochemistry 44:15871-15879. doi: 10.1021/bi051268b
32. Mitra A, Sept D (2004) Localization of the antimitotic peptide and depsipeptide binding site on β -tubulin. Biochemistry 43:13955-13962. doi: 10.1021/bi0487387
33. Spartan'08, Wavefunction Inc, Irvine, CA; Shao Y, Molnar LF, Jung Y, Kussmann J, Ochsenfeld C, Brown ST, Gilbert ATB, Slipchenko LV, Levchenko SV, O'Neill DP, DiStasio RA Jr, Lochan RC, Wang T, Beran, GJO, Besley NA, Herbert JM, Lin CY, Van Voorhis T, Chien SH, Sodt A, Steele RP, Rassolov VA, Maslen PE, Korambath PP, Adamson RD, Austin B, Baker J, Byrd EFC, Dachsel H, Doerksen RJ, Dreuw A, Dunietz BD, Dutoi AD, Furlani TR, Gwaltney SR, Heyden A, Hirata S, Hsu C-P, Kedziora G, Khalliulin RZ, Klunzinger P, Lee AM, Lee MS, Liang WZ, Lotan I, Nair N, Peters B, Proynov EI, Pieniazek PA, Rhee YM, Ritchie J, Rosta E, Sherrill CD, Simmonett AC, Subotnik JE, Woodcock III HL, Zhang W, Bell AT, Chakraborty AK, Chipman DM, Keil FJ, Warshel A, Hehre WJ, Schaefer HF, Kong J, Krylov AI, Gill PMW, Head-Gordon M (2006) Advances in methods and algorithms in a modern quantum chemistry program package. Phys Chem Chem Phys 8:3172-3191. doi: 10.1039/B517914A
34. Mitchell D, Hay LA, Koenig TM, McDaniel S, Nissen JS, Audia JE (2005) Classical and dynamic resolution of 1-amino-3-methyl-1,3,4,5-tetrahydrobenzo[d] azepin-2-one. Tetrahedron: Asymmetry 16:3814-3819. doi: 10.1016/j.tetasy.2005. 10.037
35. Lim HJ, Gallucci JC, RajanBabu TV (2010) Annulated diketopiperazines from dipeptides or Schöllkopf reagents via tandem cyclization-intramolecular N-arylation. Org Lett 12:2162-2165. doi: 10.1021/ol100663
36. Malkov AV, Vranková K, Černý M, Koč ovský P (2009) On the selective N-methylation of BOC-protected amino acids. J Org Chem 74:8425-8427. doi: 10.1021/jo9016293
37. Mangette JE, Johnson MR, Le V-D, Shenoy RA, Roark H, Stier M, Belliotti T, Capiris T, Guzzo PR (2009) The preparation of optically active α -amino 4H-[1,2,4]oxadiazol-5-ones from optically active α -amino acids. Tetrahedron 65:9536-9541. doi: 10.1016/j.tet.2009.09.045
38. Hamel E (2003) Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem Biophys 38:1-22. doi: 10.1385/CBB:38:1:1